Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib PK in Hepatic Impairment
NCT02095587Phase 1Completed
- Sponsor
- Secura Bio
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of duvelisib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma (FL) (4 arms), sponsored by Secura Bio. Primary endpoint: Pharmacokinetic parameters of IPI-145 and its primary metabolite, IPI-656 at 72 hours. Started Mar 2014; status: completed.
02
Drugs
duvelisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02095587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095587.